Severe Lower Gastrointestinal Bleeding in Crohn's Disease: Successful Control With Infliximab
TO THE EDITOR: Acute lower GI bleeding is an uncommon but potentially life-threatening complication of Crohn's disease (CD) occurring in about 1.5% of cases (1, 2) . The severity is judged on the basis of the need for transfusion of several units of blood. It represents a therapeutic challenge. A conservative approach has generally been advocated in view of the likelihood of spontaneous cessation of the bleeding. However, in some cases, particularly because of the risk of recurrence and multiple or diffuse bleeding lesions not allowing endoscopic treatment, there is a place for a drug with rapid mucosal healing potential (3) (4) (5) . We describe two patients with severe bleeding caused by CD treated with infliximab.
The first patient was a 28-yr-old white woman with a 3-yr history of CD involving the terminal ileum and the colon who was admitted for massive rectal bleeding. She also suffered from recurrent perineal fistula. Two days before admission, she developed profuse rectal bleeding. On admission, the blood count showed a hemoglobin of 7.6 g/dl. Bleeding originating from upper GI tract or anal lesions was excluded. Colonoscopy showed a diffuse colonic involvement with multiple deep round or serpiginous ulcers located particulary in the cecum and the left colon. The colon contained a significant amount of blood, but the source of bleeding was not localized. After transfusion of two units of blood, p.o. budesonide (9 mg/day) and azathioprine (125 mg/day) were started. Because the patient continued to bleed, requiring three more units of blood and because of persistent fistula discharge, a treatment with infliximab infusion (5 mg/kg) was started. The patient left the hospital without recurrence of bleeding 4 days after the first infusion. She was readmitted 10 days later for a rebleeding and a hemoglobin of 6.1 g/dl. A proctosigmoidoscopy showed circumferential ulcers and copious amounts of blood and melena without identifying an obvious site of bleeding. After transfusion of five units of blood, a second infusion of infliximab (5 mg/kg), 14 days after the first one, was administered. The patient was discharged without bleeding recurrence. A third infusion was administered 1 month later. At this time, there was no bleeding recurrence, and proctosigmoidoscopy revealed a complete healing of colonic ulcerations. The patient remains disease free without evidence of bleeding 5 months later.
The second patient was a 59-yr-old white woman with a 9-yr history of CD involving the colon who was admitted for rectal bleeding, diarrhea, and anemia. One month before admission, she noted increased diarrhea and frequent red blood per rectum. Medication on admission included oral steroids, metronidazole, and ciprofloxacine. On admission, the blood count showed a hemoglobin of 8 g/dl. Upper GI endoscopy was normal. Colonoscopy showed multiple deep round and large ulcers located in the right colon with blood in the lumen, but no site of bleeding was identified. The rectum was normal. After transfusion of four units of blood, azathioprine (100 mg/day) was started and first infusion of infliximab (5 mg/kg) was given. Diarrhea decreased, and rectorragia disappeared 4 days after infusion. Four months later, the patient had a relapse of CD but without evident bleeding. She was successfuly treated with a new infusion of infliximab.
The two cases show efficacy of infliximab in hemorragic forms of CD. This treatment allowed not only to control bleeding but also to scar underlying lesions. The primary treatment of severe lower GI bleeding in CD is determined by the severity and persistence of bleeding as well as the risk for recurrence. Localization of the site of bleeding is essential whether endoscopic therapy, surgery, or medical management is attempted. Endoscopic evaluation is preferable, if feasible, as it will provide a broader assessment of extent of disease as well as having a reasonable likelihood of identifying the site of bleeding with possible therapeutic intervention (2) . If the acute bleeding ceases, an interval to attempt pharmacological therapy may be available, permitting treatment of the underlying CD. In our first case, severe acute bleeding resolved in two successive occasions a few days after infliximab infusion. This result may still be fortuitous. However, the fact that it occurred twice and the complete scarring of the lesion that was obtained later are arguments for a direct effect of infliximab, both in the early control of bleeding and in the absence of further recurrence. In our second case, mild-tomoderate bleeding had lasted for more than 1 month. It stopped within 4 days after infliximab infusion and did not recur. Again, such rapid effect after a longstanding bleeding is an argument for a specific role of infliximab.
In conclusion, our two cases show that new therapies such as infliximab, which may produce relatively rapid mucosal healing, may be beneficial and offer treatment alternative to surgery in either acute massive or chronic refractory bleeding in CD.
Cecal Volvulus After Colonoscopy
TO THE EDITOR: Transient abdominal discomfort after colonoscopy occurs frequently but rarely requires evaluation. Persistent or worsening abdominal pain, especially if biopsy or polypectomy was performed, prompts concern about colonic perforation. Cecal volvulus is an extremely rare but potentially deadly complication of colonoscopy. We report the fourth case of cecal volvulus after colonoscopy and the first in a patient with intestinal nonrotation.
A 58-yr-old woman underwent screening total colonoscopy, and a 5-mm sessile polyp was completely removed from the sigmoid colon. The patient presented to the emergency room 12 h after colonoscopy complaining of diffuse abdominal pain, bloating, and nausea. On examination, she was afebrile, her abdomen was distended, bowel sounds were present, and there were no peritoneal signs. The white blood cell count was normal. Plain abdominal radiographs revealed a markedly dilated colon with no evidence of free intraperitoneal air. The symptoms were attributed to retained gas from the colonoscopy. At 24 h after colonoscopy, the patient returned to the emergency department. At this time, her abdomen was more distended, diffusely tender to palpation, and she had high-pitched hypoactive bowel sounds. Abdominal radiographs revealed increased distension of the colon and dilated small intestine with air-fluid levels (Fig. 1) . Laparotomy confirmed cecal volvulus with necrosis. The cecum had rotated around the ileocecal artery in a counter clockwise direction. The duodenum passed straight down to the right of the midline with the small bowel on the right side of the abdomen and the colon on the left. The cecum had a redundant mesentery and was not retroperitoneal. A right hemicolectomy with primary anastomosis was performed, and the patient had an excellent recovery.
Minor complications are reported to occur in only 5% of colonoscopies, and major morbidity is only 0.3% (1-3). Cecal volvulus after colonoscopy is extremely rare with only three reports in the English literature (4 -6). Although absence of free intraperitoneal air on plain radiographs lessens the likelihood of colonic perforation and is reassuring, our case demonstrates that absence of free air does not rule out a significant complication. In this case, the presence of a cecal volvulus was missed twice on the initial interpretation of plain films.
The absence of normal fixation of the cecum increases the likelihood of cecal volvulus. Our patient had intestinal nonrotation and a mobile cecum making it susceptible to vol- Figure 1 . Plain flat and upright abdominal radiographs 24 h after after colonoscopy. Distension of the colon has increased, and dilated loops of small intestine with air-fluid levels have developed. The characteristic "coffee bean" appearance is consistent with cecal volvulus.
